Biotech Turns Failed Drug Trial Into AI Win for Patients

Most companies bury their failures, but Verge Genomics just turned theirs into a gift for science.

When the biotech company's ALS drug trial failed last month, with a third of patients dropping out due to side effects, co-founder Alice Zhang made an unusual choice. Instead of quietly moving on, Verge published a detailed postmortem explaining exactly what went wrong.

"While the temptation is strong, when a trial doesn't meet the anticipated end points, to kind of look away and not talk about it, we think there are a lot of learnings that can come," Zhang told STAT News. She believes these lessons matter not just for Verge, but for the entire field of neurodegenerative disease research.

But Verge didn't stop at transparency. They transformed their failed trial data into an AI benchmarking dataset that other companies can use to improve their own research.

The company has spent over a decade analyzing the networks of genes that cause diseases like Parkinson's, ALS, and Alzheimer's. That work has already produced results, including two drug targets that pharmaceutical giant Eli Lilly added to its pipeline in 2024.

Now Verge has unveiled a new AI model that solves one of clinical trials' biggest headaches: patient stratification. This means figuring out which patients are most likely to respond to a treatment before the trial even begins.

The Ripple Effect

Getting patient selection wrong wastes years of research time and millions of dollars. More importantly, it delays treatments that could save lives.

By sharing their failure data openly, Verge is helping other researchers avoid similar pitfalls. Their new AI tool could make neurology trials more efficient, meaning potentially life-saving drugs reach patients faster.

This approach flips the usual script in pharmaceutical development, where failures often disappear behind closed doors. Verge is proving that transparency can accelerate progress for everyone working on devastating diseases like ALS and Alzheimer's.

The company's willingness to learn publicly from setbacks while continuing to innovate shows how failure, when handled right, can become fuel for breakthrough solutions.